Clinical trial
Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00045695 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00045695 |
|---|---|
| Title | Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia |
| Official title | A Phase II Study Of PS-341 (NSC 681239) In Patients With Untreated Or Relapsed Waldenstrom's Macroglobulinemia |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH Eastern Cooperative Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 27 |
| Start date | Aug 1, 2002 |
| Primary completion | Mar 1, 2006 |
| Completion | Dec 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | May 17, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: